Early acute T cell-mediated rejection and kidney allograft outcomes
Kidney International · 2026-10 · 110 (4) · 946-963
DOI: 10.1016/j.kint.2026.06.042 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Kidney International, 2026-10. Verfasst von Chuxiao Chen und 24 weiteren Autor:innen. Beteiligte Einrichtung: Thomas E. Starzl Transplantation Institute, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA; Department of Surgery, Univer…. Hauptthemen laut MEDLINE: Kidney Transplantation, Graft Rejection, Graft Survival, T-Lymphocytes. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: ISCIII, NIAID, FWO.
Abstract (Originalsprache)
INTRODUCTION: Despite the prevalent notion that early acute T cell-mediated rejection (TCMR) in kidney transplant patients is clinically benign, how it responds to treatment and whether treatment responses impact long-term graft survival remain unclear and poorly characterized. METHODS: To comprehensively address this issue, we conducted an observational cohort study of all adult patients who underwent kidney transplantation between January 2013 and December 2019 across six centers in the United States and Europe. We evaluated the incidence of TCMR in the first post-transplant year, assessed clinical and histological responses to treatment, and examined their association with long-term graft outcomes. RESULTS: Among 5,762 patients undergoing 9,780 biopsies, 790 (13.6%) developed TCMR. Despite treatment, 36% of patients demonstrated clinical deterioration and 32% had persistent TCMR on follow-up biopsy, indicating frequent treatment resistance. Clinical and histologic responses were frequently discordant. While only 51% of patients with clinical improvement had no rejection, 37% with clinical deterioration also showed no rejection. TCMR was significantly associated with worse graft survival (death-censored graft loss hazard ratio 2.84, 95% confidence interval 2.38-3.3). Importantly, persistent TCMR conferred a substantially higher risk of graft loss compared with responsive TCMR (3.21, 2.19-4.71) independent of clinical response and other confounders. This association was consistent across subgroups and supported by time-dependent and landmark analyses. Increasing tubulointerstitial inflammation (Banff Δ 't+i' scores) demonstrated a graded association with adverse outcomes, and trajectory analyses showed a stepwise increase in graft loss with persistent or recurrent inflammation. CONCLUSIONS: TCMR is common, frequently treatment-resistant, and persistent TCMR is strongly associated with inferior long-term graft survival. Clinical improvement often failed to reflect histologic response. These findings challenge the notion that TCMR is clinically benign and identify persistent inflammation as a key driver of graft loss, underscoring the need for response guided monitoring and more effective targeted therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Thomas E. Starzl Transplantation Institute, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA; Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA;…
- Thomas E. Starzl Transplantation Institute, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA; Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
- Renal Electrolyte Division, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
- Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium.
- Division of Nephrology, Department of Medicine, Stanford University, Stanford, California, USA.
- Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Förderung
- ISCIII
- NIAID
- FWO
Zitieren
APA
Chen, C., Elias, C., Keyser, M., Wellekens, K., Rothstein, D. M., Lakkis, F. G., Randhawa, P., Koshy, P., Mayer, K. A., Diebold, M., Torres, I. B., Moreso, F., Molinari, M., Mehta, R., Hariharan, S., Gunabushanam, V., Tevar, A. D., Kuypers, D., Abou Daya, K. I., …, & Cherukuri, A. (2026). Early acute T cell-mediated rejection and kidney allograft outcomes. Kidney International, 110(4), 946-963. https://doi.org/10.1016/j.kint.2026.06.042
Vancouver
Chen C, Elias C, Keyser M, Wellekens K, Rothstein DM, Lakkis FG, et al. Early acute T cell-mediated rejection and kidney allograft outcomes. Kidney International. 2026;110(4):946-963. doi:10.1016/j.kint.2026.06.042
BibTeX
@article{Chen2026,
author = {Chen, Chuxiao and Elias, Charbel and Keyser, Michelle and Wellekens, Karolien and Rothstein, David M and Lakkis, Fadi G and Randhawa, Parmjeet and Koshy, Priyanka and Mayer, Katharina A and Diebold, Matthias and Torres, Irina B and Moreso, Francesc and Molinari, Michele and Mehta, Rajil and Hariharan, Sundaram and Gunabushanam, Vikraman and Tevar, Amit D and Kuypers, Dirk and Abou Daya, Khodor I and Schaub, Stefan and Böhmig, Georg A and Thaunat, Olivier and Bestard, Oriol and Naesens, Maarten and Cherukuri, Aravind},
title = {Early acute T cell-mediated rejection and kidney allograft outcomes},
journal = {Kidney International},
year = {2026},
volume = {110},
number = {4},
pages = {946--963},
doi = {10.1016/j.kint.2026.06.042}
}
EUVIMED